Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

53.64USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$53.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,958,247
52-wk High
$70.04
52-wk Low
$46.95

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 31.13 34.39
EPS (TTM): 2.74 -- --
ROI: 18.60 15.55 14.96
ROE: 30.97 16.92 16.52

Bristol-Myers must face lawsuit alleging underpaid Medicaid rebates

Bristol-Myers Squibb Co must face a whistleblower lawsuit alleging that the drugmaker for years knowingly underpaid rebates the company owed to state Medicaid programs, a federal judge has ruled.

Nov 30 2018

Bristol-Myers Squibb says cancer drug combination fails late-stage trial

Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

Nov 26 2018

UPDATE 1-Bristol-Myers Squibb says cancer drug combination fails late-stage trial

Nov 26 Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

Nov 26 2018

Bristol-Myers Squibb says cancer drug combination fails maintenance trial

Nov 26 Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

Nov 26 2018

Incyte loses trade-secret case against Flexus over cancer drug

A Delaware state court jury has rejected pharmaceutical company Incyte Corp's claims that rival Flexus Biosciences Inc was unjustly enriched by stealing cancer drug research trade secrets from it before Bristol-Myers Squibb Co acquired Flexus in 2015.

Nov 08 2018

Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit: sources

FRANKFURT/LONDON German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Nov 08 2018

UPDATE 1-Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources

* Bristol Myers to focus on high-margin prescription drugs (Adds context, details on valuation)

Nov 08 2018

Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources

FRANKFURT/LONDON, Nov 8 German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Nov 08 2018

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Oct 25 2018

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Oct 25 2018

Earnings vs. Estimates